Global Onchocerciasis Market, By Diagnosis (Physical Examination, Skin Biopsy, Mazzotti Test, Nodulectomy, PCR Test, Others), Treatment (Medication, Supportive Care, Others), Drug (Ivermectin, Moxidectin, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Onchocerciasis Market Analysis and Size
The global onchocerciasis market is expected to witness significant growth during the forecast period. Rising prevalence of eye and skin disease worldwide and emerging markets are the factors responsible for the expansion of this market. The growth of global onchocerciasis market enhanced by the growing cases of river blindness and rise in R&D activities conducted by many pharmaceuticals’ companies. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global onchocerciasis market in the forecast period 2022-2029. The expected CAGR of global onchocerciasis market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Onchocerciasis also known as river blindness which is caused by parasitic worm Onchocerca volvulus. This disease affects both the skin and eyes and transmitted by repeated bites of infected blackflies (Simulium spp.). When female blackfly bites an onchocerciasis infected patient during a blood meal it also ingests microfilariae which develop further in the blackfly and again the blackfly bites another normal person and spread the infection. Symptoms of onchocerciasis includes disfiguring skin conditions, sever itching and visual impairment, including permanent blindness..
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Physical Examination, Skin Biopsy, Mazzotti Test, Nodulectomy, PCR Test, Others), Treatment (Medication, Supportive Care, Others), Drug (Ivermectin, Moxidectin, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Allergan,Inc (Ireland), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Abbott (U.S.), bioMérieux (France), BD (U.S.), Danaher (U.S.), Thermo Fisher Scientific Inc., (U.S.), Siemens (Germany), Agilent Technologies, Inc, (U.S.), Merck KGaA (Germany), Fluidigm (U.S.). QIAGEN (Germany), Bio-Rad Laboratories, Inc. (U.S.), Cytiva (U.S.), Stryker (U.S.)
|
|
Market Opportunities
|
|
Global Onchocerciasis Market Dynamics
Drivers
- Increased Incidence of River Blindness
As per the reports of WHO, around 99% of infected people live in 31 African countries and the syndrome also exist in Latin America and Yemen countries. “Global Burden of Disease Study” estimated in 2017 that around 20.9 million cases of Onchocerca volvulus infections witnessed worldwide in which 14.6 million people are infected with skin disease and 1.15 million had vision loss. Thus, it boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Demands of Diagnostic Tests
The increasing demands for diagnostic tests such as the use of a biopsy on the skin with regular saline is boosting the market growth. Another procedure includes searching for the larvae in the eye as well as sensing bumps under the skin which turns out to be a sign of adult worms. Thus, all these diagnostic procedures boost the growth of the market.
- Increasing Demand for Retail Pharmacies
The rise in the number of narcotic drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Complications of Onchocerciasis
Several complications are associated with onchocerciasis and severe side effects are associated with the treatment of onchocerciasis. Ocular complications of onchocerciasis include pannus formation, blindness secondary to keratitis, and corneal fibrosis. It also includes posterior segment complications such as chorioretinitis, open-angle glaucoma, intraretinal deposits, and optic atrophy.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global onchocerciasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global onchocerciasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Onchocerciasis Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
Pericarditis witnessed to be widespread during the pandemic but was rarely seen in the post-acute period, on the other hand minor pericardial effusions seem to be very common during the COVID-19 post-acute period. Additionally, post-COVID pericarditis is found to be linked to continuing inflammation. Thus, overall, COVID-19 had a major impact on the global pericarditis drugs market.
Global Onchocerciasis Market Scope
The global onchocerciasis market is segmented on the basis of treatment, diagnosis, drug, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Physical Examination
- Skin Biopsy
- Mazzotti Test
- Nodulectomy
- PCR Test
- Others
Treatment
- Medication
- Supportive Care
- Others
Drug
- Ivermectin
- Moxidectin
- Others
Route of Administration
- Oral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Onchocerciasis Market Regional Analysis/Insights
The global onchocerciasis market is analysed and market size insights and trends are provided by treatment, diagnosis, drug, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global onchocerciasis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific and Africa has been witnessing a highest growth for global onchocerciasis market throughout the forecasted period due to increased government and WHO awareness programs and number of generic drugs.
North America dominates the market due to the increased prevalence of onchocerciasis and presence of key manufacture of the product.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Onchocerciasis Market Share Analysis
The global onchocerciasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global onchocerciasis market.
Key players operating in the global onchocerciasis market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Allergan,Inc (Ireland)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Abbott (U.S.)
- bioMérieux (France)
- BD (U.S.)
- Danaher (U.S.)
- Thermo Fisher Scientific Inc., (U.S.)
- Siemens (Germany)
- Agilent Technologies, Inc, (U.S.)
- Merck KGaA (Germany)
- Fluidigm (U.S.)
- QIAGEN (Germany)
- Bio-Rad Laboratories, Inc. (U.S.)
- Cytiva (U.S.)
- Stryker (U.S.)
SKU-